NeuroDerm Company Profile (NASDAQ:NDRM)

About NeuroDerm

NeuroDerm logoNeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa/carbidopa (LD/CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, which is for the treatment of patients suffering from severe Parkinson's disease; ND0612L, which is for the treatment of patients at the moderate stage of Parkinson's disease, and ND0701, which is an apomorphine-based product. The Company is also developing a product candidate, ND0801, to treat cognition disorders associated with CNS diseases. The Company's delivery devices include CRONO ND, which is a fixed-dose belt pump, and CRONO Twin ND, which is an adjustable belt pump.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NDRM
  • CUSIP:
Key Metrics:
  • Previous Close: $18.55
  • 50 Day Moving Average: $17.70
  • 200 Day Moving Average: $17.25
  • 52-Week Range: $11.76 - $21.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.76
  • P/E Growth: 0.00
  • Market Cap: $402.61M
  • Outstanding Shares: 21,704,000
  • Beta: 1
  • Return on Equity: -21.51%
  • Return on Assets: -20.60%
  • Current Ratio: 17.06%
  • Quick Ratio: 17.06%
Additional Links:
Companies Related to NeuroDerm:

Analyst Ratings

Consensus Ratings for NeuroDerm (NASDAQ:NDRM) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $30.67 (65.32% upside)

Analysts' Ratings History for NeuroDerm (NASDAQ:NDRM)
DateFirmActionRatingPrice TargetDetails
9/6/2016Jefferies GroupBoost Price TargetBuy$28.00 -> $40.00View Rating Details
5/29/2016Roth CapitalReiterated RatingBuyView Rating Details
4/2/2016Oppenheimer Holdings Inc.Initiated CoverageBuyView Rating Details
11/10/2015Raymond James Financial Inc.Initiated CoverageOutperform$28.00View Rating Details
12/9/2014Cowen and CompanyInitiated CoverageOutperformView Rating Details
(Data available from 10/22/2014 forward)


Earnings History for NeuroDerm (NASDAQ:NDRM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/25/2016Q2($0.32)($0.32)ViewListenView Earnings Details
5/26/2016Q1($0.35)($0.25)ViewListenView Earnings Details
3/31/2016Q4($0.29)$0.31ViewListenView Earnings Details
11/11/2015Q315($0.34)($0.49)ViewListenView Earnings Details
8/6/2015Q215($0.20)($0.34)ViewListenView Earnings Details
5/27/2015Q115($0.28)($0.09)ViewListenView Earnings Details
4/2/2015($0.35)($2.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NeuroDerm (NASDAQ:NDRM)
Current Year EPS Consensus Estimate: $-1.49 EPS
Next Year EPS Consensus Estimate: $-1.9 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.29)($0.29)($0.29)
Q2 20162($0.40)($0.34)($0.37)
Q3 20162($0.40)($0.36)($0.38)
Q4 20162($0.60)($0.42)($0.51)
(Data provided by Zacks Investment Research)


Dividend History for NeuroDerm (NASDAQ:NDRM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for NeuroDerm (NASDAQ:NDRM)
No insider trades for this company have been tracked by


Latest Headlines for NeuroDerm (NASDAQ:NDRM)
News IconNeuroDerm Ltd. (NDRM) Updated Analyst Coverage - NewsDen (NASDAQ:NDRM) - October 20 at 6:43 PM
News IconConsensus Take: NeuroDerm Ltd. (NASDAQ:NDRM) Earnings & Ratings Watch - CSZ News (NASDAQ:NDRM) - October 19 at 6:41 PM
News IconNeuroDerm Ltd. (NDRM) Analyst Review - NewsDen (NASDAQ:NDRM) - October 17 at 11:29 AM
News IconLatest Analyst Ratings For NeuroDerm Ltd. (NDRM) - The De Soto Edge (NASDAQ:NDRM) - October 16 at 10:46 AM
News IconBroker Roundup For NeuroDerm Ltd. (NDRM) - The De Soto Edge (NASDAQ:NDRM) - October 12 at 6:19 PM
News IconLatest Analyst Reports On NeuroDerm Ltd. - NewsDen (NASDAQ:NDRM) - October 7 at 6:06 PM
News IconAnalysts Weigh in on NeuroDerm Ltd. (NASDAQ:NDRM) - Recall News (NASDAQ:NDRM) - October 5 at 11:34 AM logoNeuroDerm Provides Updates on ND0612 Long-Term Safety Trial and Submission of Marketing Applications (NASDAQ:NDRM) - September 29 at 6:19 PM
News IconNeuroDerm Ltd. (NDRM) Updated Broker Price Targets - The De Soto Edge (NASDAQ:NDRM) - September 29 at 11:31 AM logoNeuroDerm (NDRM) Will Require Additional Time to Activate BeyoND Clinical Sites in Certain Countries - (NASDAQ:NDRM) - September 29 at 11:31 AM
News IconPattern Worth Mentioning: Neuroderm Ltd's Stock Formed A Several Months Bullish Multiple Top Pattern - Chester News (NASDAQ:NDRM) - September 23 at 5:55 PM logoNeuroDerm (NDRM) Announces Successful Results in Using ND0612 as PD Treatment in Home Setting - (NASDAQ:NDRM) - September 23 at 5:55 PM logoNeuroDerm’s ND0612 Mini-Pump Delivery System Successfully Used by Parkinson’s Disease Patients in Home Setting (NASDAQ:NDRM) - September 22 at 6:02 PM logoNeuroDerm to Present ND0612 Data at 4th World Parkinson Congress Demonstrating Ease of Use of Mini-Pump Delivery System (NASDAQ:NDRM) - September 19 at 10:49 AM logoNeuroDerm Ltd. :NDRM-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 (NASDAQ:NDRM) - September 14 at 10:38 AM
News IconAnalysts Place NeuroDerm Ltd. (NASDAQ:NDRM) Under the Lens of the Microscope - Post News (NASDAQ:NDRM) - September 12 at 6:03 PM
News IconStock Update on Earnings & Estimates for NeuroDerm Ltd. (NASDAQ:NDRM) - Frisco Fastball (NASDAQ:NDRM) - September 10 at 10:41 AM logoNeuroDerm (NDRM): Hiking PT 43% After Management Meeting - Jefferies (NASDAQ:NDRM) - September 6 at 11:04 AM
News IconNeuroDerm Ltd. (NASDAQ: NDRM) stock downgraded to Sell - BNB Daily (blog) (NASDAQ:NDRM) - September 1 at 9:32 AM logoHere’s What We’re Looking At From Neuroderm Ltd (NDRM)’s Parkinson’s Trial (NASDAQ:NDRM) - August 29 at 6:12 PM logoHere's What We're Looking At From Neuroderm Ltd (NASDAQ:NDRM)'s Parkinson's Trial - Market Exclusive (NASDAQ:NDRM) - August 27 at 10:43 AM logoSono-Tek Holds Annual Shareholders Meeting and Confirms Second Quarter Fiscal 2017 Sales Guidance (NASDAQ:NDRM) - August 26 at 6:08 PM logoHere’s What We’re Looking At From Neuroderm Ltd (NASDAQ:NDRM)’s Parkinson’s Trial (NASDAQ:NDRM) - August 26 at 6:08 PM
News IconNeuroDerm Initiates Patient Enrollment In A Phase III Trial Of ND0612L For The Treatment Of Parkinson's Disease (NASDAQ:NDRM) - August 26 at 9:26 AM logoNeuroDerm (NDRM) Commences Enrollment in ND0612L Phase 3 as Parkinson's Disease Treatment (NASDAQ:NDRM) - August 26 at 9:26 AM logoNeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:NDRM) - August 25 at 6:22 PM logoNeuroDerm reports 2Q loss (NASDAQ:NDRM) - August 25 at 11:30 AM logoNeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson’s Disease (NASDAQ:NDRM) - August 25 at 11:30 AM logoCan NeuroDerm Ltd. (NASDAQ:NDRM) Meet Analysts Expectations? - Stocks Daily (NASDAQ:NDRM) - August 21 at 10:33 AM logoDurable Goods, Wholesale Trade, on Next Week's Docket - (NASDAQ:NDRM) - August 19 at 6:21 PM logoNeuroDerm to Host Second Quarter 2016 Financial Results Conference Call on August 25, 2016 (NASDAQ:NDRM) - August 11 at 9:37 AM logoBest Stocks: Vale S.A. (NYSE:VALE), NeuroDerm Ltd. (NASDAQ:NDRM), Luminex Corporation (NASDAQ:LMNX ... - KC Register (NASDAQ:NDRM) - August 2 at 6:42 PM logoStock Runners: NeuroDerm Ltd. (NASDAQ:NDRM), The Walt Disney Company (NYSE:DIS), MGIC Investment (NYSE ... - KC Register (NASDAQ:NDRM) - July 28 at 9:38 AM logo7:04 am NeuroDerm announces the USPTO has issued a patent related to its ND0701 program (NASDAQ:NDRM) - July 27 at 7:04 AM logoNeuroDerm Announces Issuance of a New U.S. Patent for Aqueous Apomorphine Covering Concentrated Subcutaneously Delivered Pharmaceutical Compositions (NASDAQ:NDRM) - July 27 at 7:00 AM logoNeuroDerm Announces Start of Bioequivalence Trial... (NASDAQ:NDRM) - July 26 at 6:42 PM logoNeuroDerm Announces Start of Bioequivalence Trial in Healthy Volunteers of ND0701, a New Continuous Subcutaneously Delivered Apomorphine Product Candidate for the Treatment of Advanced Parkinson’s Disease (NASDAQ:NDRM) - July 26 at 8:08 AM
News IconEquity Roundup: Stock Performance Focus on NeuroDerm Ltd. (NASDAQ:NDRM) - Press Telegraph (NASDAQ:NDRM) - July 23 at 10:17 AM
News IconNeuroderm Limited Ord (NASDAQ:NDRM) Short Interest Decreased By 0.85% - Consumer Eagle (NASDAQ:NDRM) - July 21 at 6:42 PM
News IconInvestor Update: Earnings and Target Price Recap on NeuroDerm Ltd. (NASDAQ:NDRM) - Press Telegraph (NASDAQ:NDRM) - July 21 at 6:42 PM
News IconNeuroDerm Ltd. (NASDAQ:NDRM) Wall Street Analyst Recommendation Outlook - TGP (NASDAQ:NDRM) - July 18 at 6:32 PM
News IconNeuroderm Ltd Formed a Bullish Inverse H&S Pattern, Could Be One of The Best Performers Soon - Press Telegraph (NASDAQ:NDRM) - July 18 at 11:44 AM logoNeuroDerm Ltd. Stock Momentum at Critical Inflection Point - CML News (NASDAQ:NDRM) - July 15 at 11:13 AM
News IconNeuroDerm Ltd. (NASDAQ:NDRM) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:NDRM) - July 15 at 11:13 AM
News IconHow Many Neuroderm Ltd (NASDAQ:NDRM)'s Analysts Are Bearish? - Consumer Eagle (NASDAQ:NDRM) - July 12 at 6:40 PM
News IconWall Street Ratings and Target Price Views on NeuroDerm Ltd. (NASDAQ:NDRM) - Telanagana Press (NASDAQ:NDRM) - July 11 at 11:02 AM logoNeuroDerm (NDRM) Names Tami Yardeni as COO - (NASDAQ:NDRM) - July 7 at 6:26 PM
News IconCan NeuroDerm Ltd. (NASDAQ:NDRM) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:NDRM) - July 7 at 6:26 PM logoNeuroDerm (NDRM) Names Tami Yardeni as COO (NASDAQ:NDRM) - July 6 at 6:38 PM logoNeuroDerm Announces Additions to Management Team (NASDAQ:NDRM) - July 6 at 11:03 AM


NeuroDerm (NASDAQ:NDRM) Chart for Saturday, October, 22, 2016

Last Updated on 10/22/2016 by Staff